



## **ALX Oncology to Present ALX148 Clinical Biomarker Data at the 34<sup>th</sup> Annual Meeting of the Society for Immunotherapy of Cancer (SITC)**

**DUBLIN, Ireland and BURLINGAME, Calif. – October 2, 2019** – ALX Oncology, a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced that it will be presenting clinical biomarker data from its ongoing ALX148 phase 1 clinical program at the SITC 34<sup>th</sup> Annual Meeting, November 6-10, 2019 at the Gaylord National Hotel & Convention Center in National Harbor, Maryland.

### **Poster Presentation Information**

**Title:** Pharmacodynamic biomarker characterization of ALX148, a CD47 blocker, in combination with established anticancer antibodies in patients with advanced malignancy (*Abstract P449*)

**Date:** Friday, November 8, 2019

**Time:** 7:00 am – 8:00 pm

### **About ALX Oncology**

ALX Oncology is a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint mechanism, which is exploited by cancer cells to evade the immune system. Our lead candidate, ALX148, is a first-in-class fusion protein comprised of an engineered high affinity CD47 binding domain of SIRP $\alpha$  linked to an inactive Fc region of human immunoglobulin. ALX148 is designed to maximize the clinical benefit of antibody-based therapies and is in clinical development for a broad range of tumor types. [www.alxoncology.com](http://www.alxoncology.com)

### **Contact:**

Karen Sharma

MacDougall

(781) 235-3060

[alx@macbiocom.com](mailto:alx@macbiocom.com)